Proteostasis Therapeutics Inc (PTI)
One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company.
4 buy
1 hold
1 sell
- Leerink Swann reissued a buy rating
- HC Wainwright started coverage and issued buy rating
- Guggenheim started coverage and issued neutral rating
- Robert W. Baird started coverage on shares of Proteostasis
- Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating
- JPMorgan Chase & Co. purchased a new stake in shares of Proteostasis Therapeutics Inc (NYSE:PTI) valued at approximately $632,000.
- Bioventures Ltd Novartis bought 375,000 shares of the company’s stock.
- BlackRock Fund Advisors acquired a new position in shares of Proteostasis Therapeutics valued at about $130,000.
- Director Franklin M. Berger purchased 25,000 shares of the stock.
The stock’s market capitalization is $74.41 million.
Proteostasis Therapeutics, Inc is a United States-based biopharmaceutical company developing small molecule therapeutics to treat diseases caused by defects in protein processing. The Company identifies selective drug candidates that modulate the proteostasis imbalance in the cell by combining the Disease-Relevant Translation, DRT platform, which is a phenotypic screening approach based on the use of functionally pertinent cellular assays and disease relevant models. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts.
http://ir.proteostasis.com/phoenix.zhtml?c=254052&p=irol-irhome
Proteostasis Therapeutics (NASDAQ:PTI) opened at 19.26 on Friday. Proteostasis Therapeutics has a 12-month low of $5.27 and a 12-month high of $20.45. The company has a 50-day moving average price of $12.95 and a 200-day moving average price of $10.31. The firm’s market cap is $368.62 million.
Collaboration and consulting agreements...
OMG! I was actually looking for PTI a political party, but fortunately I found this great post.
Proteostasis Therapeutics Inc (NASDAQ:PTI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future.
All of our revenue during the three months ended March 31, 2016 and 2015 has been derived from our collaboration agreements with Astellas and Biogen. Revenue was $1.2 million for the three months ended March 31, 2016, compared to $0.8 million for the three months ended March 31, 2015. The increase of $0.4 million was the result of an increase of $0.3 million of revenue recognized from our collaboration with Astellas and an increase of $0.1 million of revenue recognized from our collaboration with Biogen.
See: http://www.sec.gov/Archives/edgar/data/1445283/000119312516590536/d171953d10q.htm